Why Is Eco Animal Health Group PLC Up on 11 Nov 2026?

Eco Animal Health Group PLC shares rose 5.10% on 11 Nov 2026, with LSE:EAH among the notable risers on the day. The move follows the company's results for the year ended 31 March 2026, which showed growth across Revenue and earnings.

Revenue rose to £87.52 million from £79.59 million, adjusted EBITDA increased 16% to £8.54 million and Earnings per share rose 31% to 3.26p.

The company also launched its first vaccine, ECOVAXXIN MS, in the European Union and has already received a first order.

About Eco Animal Health Group PLC

Eco Animal Health Group PLC develops and supplies veterinary medicines for livestock. Its lead product, Aivlosin, is an antibiotic used for respiratory and intestinal infections in pigs and poultry.

The company has historically relied on Aivlosin, and its Vaccine pipeline now broadens the portfolio. For LSE:EAH, product Diversification is a key part of the next phase.

Financial Highlights

Revenue growth of around 10% was about 4% above guidance, and adjusted EBITDA was about 5% above market expectations.

Net cash was £25.43 million at 31 March 2026, providing flexibility to fund its development programmes.

North America Growth

North American revenue rose 22% year on year and was the main driver of growth.

Expanding in the world's largest animal protein markets is a central theme for the company.

ECOVAXXIN MS Launch

ECOVAXXIN MS, a vaccine that helps prevent Mycoplasma synoviae infection in poultry, launched in the EU on 30 June 2026 and has since received its first order.

Data showed a 44-week duration of immunity, and efficacy data has been submitted to the US Department of Agriculture, with US Marketing approval expected by the end of 2026.

Future Pipeline

A PCV2/Mhyo bivalent vaccine for pigs is in development, with marketing authorisation anticipated in 2028.

Adding vaccines to the antibiotic Franchise could widen the company's customer base.

Animal Health Context

Animal health is supported by long-term Demand for safe and efficient protein production, as well as by animal welfare priorities.

Vaccines are a growing part of the sector as producers look for preventative tools alongside treatments.

Business Overview and Financial Performance

Eco Animal Health reported FY26 revenue of £87.52 million, up from £79.59 million, and adjusted EBITDA of £8.54 million, up from £7.29 million. Earnings Per Share were 3.26p, compared with 2.49p.

Net cash was £25.43 million at 31 March 2026.

Strategy and Priorities

The company is broadening its range from the Aivlosin antibiotic franchise to vaccines. ECOVAXXIN MS is the first, and a bivalent pig vaccine is in development.

North America remains an important growth market, and US approval for the poultry vaccine would add a further route to market.

Regulatory Timeline

Efficacy data for ECOVAXXIN MS has been submitted to the US Department of Agriculture, and approval is expected by the end of 2026.

The pig vaccine is expected to receive marketing authorisation in 2028.

Customers

Livestock producers use Aivlosin to help manage respiratory and intestinal infections in pigs and poultry.

Vaccines complement treatment by helping to prevent disease before it occurs.

Understanding the Update

A vaccine launch moves a product from development to commercial sale, and a first order is an early sign that customers are ready to use it.

US approval would open a significant market for the poultry vaccine.

Looking Ahead

The company expects US approval by the end of 2026 and has given a timetable of 2028 for its pig vaccine.

These milestones may help broaden revenue beyond Aivlosin.

What Investors Tend to Follow

Healthcare and life sciences companies are followed through clinical progress, regulatory milestones, product launches and cash runway or revenue growth, depending on their stage. Clear timelines help investors understand what to expect next.

Key Themes to Watch

Data readouts, trial updates and approvals are the events that most often influence sentiment. For companies with commercial products, sales growth and margins are added to the list of measures that investors follow.

Key Factors to Monitor

Investors may follow US approval for ECOVAXXIN MS, early commercial orders, North American growth and development of the pig vaccine.

The company's next trading update will also provide context.

Conclusion

Eco Animal Health's 5.10% advance on 11 Nov 2026 reflects interest in its revenue growth, higher adjusted EBITDA and first vaccine launch.

With net cash of £25.43 million and a widening product range, LSE:EAH has several developments to follow. US vaccine approval and early orders are the next items to watch.